AnaptysBio Announces First-In-Human Dosing Of Anti-IL-33 Antibody

Mar 10, 2016, 08:00 ET from AnaptysBio, Inc.

SAN DIEGO, March 10, 2016 /PRNewswire/ -- AnaptysBio, Inc., a biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology, today announced first-in-human dosing of its proprietary anti-IL-33 antibody (ANB020) in a Phase I clinical trial.  The double-blind, placebo-controlled single and multiple ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ANB020 in healthy volunteers. 

Interleukin-33, or IL-33, is a pro-inflammatory cytokine that multiple studies have indicated is a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma.  IL-33 acts on white blood cell types that subsequently release atopic disease-mediating cytokines such as IL-5, IL-13 and IL-4. Since ANB020 potently inhibits IL-33 function, and acts upstream broadly across the key cell types involved in atopy, AnaptysBio believes its mechanism has potential advantages in human therapy over agents that block only a subset of the cytokines responsible for atopic diseases. The role of IL-33 signaling in asthma has been genetically validated through human studies published in the medical literature.  

Subsequent to the completion of this Phase I study, AnaptysBio plans to continue clinical development of ANB020 in patients with atopic dermatitis, peanut allergy and asthma. 

"We are pleased to advance ANB020 into the clinic and look forward to demonstrating proof-of-concept in patient studies that we plan to initiate later this year," said Hamza Suria, President & CEO of AnaptysBio.  "IL-33 signaling plays an important role in atopic diseases and we believe ANB020 is the most advanced antibody targeting the IL-33 cytokine.  ANB020 was advanced from initial concept to the clinic by AnaptysBio, and stands as a testament to our antibody discovery and development capabilities."

About AnaptysBio

AnaptysBio is an antibody development company focused on novel programs in inflammation and immuno-oncology.  In addition to ANB020, the Company's proprietary pipeline includes ANB019, an anti-IL-36 receptor antibody initially being developed for the treatment of generalized pustular psoriasis.  AnaptysBio's SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery, which is designed to replicate key features of the human immune system and overcome limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Celgene and TESARO.   


Julie Rathbun 




SOURCE AnaptysBio, Inc.